COMP <GO>
THC vs ENSG // EV/EBITDA & P/E VALUATION
Tenet Healthcare Corporation (NYSE) VS. The Ensign Group Inc. (NASDAQ) • 15-METRIC TALLY: THC 8
— ENSG 5
▲ EV/EBITDA & P/E VALUATION LEADER: THC
LAST: $273.25 (+0.99%) • MKT CAP: $21.79B
valuation
6.3x
LAST: $181.52 (-2.58%) • MKT CAP: $10.87B
valuation
17.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (THC VS. ENSG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | THC | ENSG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 20.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.60% | 18.00% | +9.60 | THC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.3x | 17.0x | -10.70 | THC | /valuation <GO> |
| Free Cash Flow Yield | 11.61% | 3.11% | +8.50 | THC | /fcf-yield <GO> |
| Operating Margin | 16.50% | 8.50% | +8.00 | THC | /operating-margins <GO> |
| Net Profit Margin | 11.10% | 6.80% | +4.30 | THC | /net-margins <GO> |
| Revenue Growth (YoY) | 3.10% | 18.80% | -15.70 | ENSG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.13% | -0.13 | ENSG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.08 | 3.73 | -1.65 | ENSG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | ENSG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.8 | 60.2 | -5.40 | ENSG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.89 | +0.08 | THC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 26.5x | -17.90 | THC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.79B | $10.87B | $10.92B | THC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | THC REV | ENSG REV | THC GROSS % | ENSG GROSS % | THC FCF | ENSG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.31B | $5.03B | — | 20.1% | $2.53B | $337.8M |
| FY 2024 | $20.68B | $4.24B | — | 20.3% | $1.12B | $156.5M |
| FY 2023 | $20.56B | $3.71B | — | — | $1.45B | $209.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
THC // BETA 0.97
ENSG // BETA 0.89